- Record: found
- Abstract: found
- Article: not found
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel
1 ,
Joseph P Costantino ,
D Lawrence Wickerham ,
Walter M Cronin ,
Reena S Cecchini ,
James N Atkins ,
Therese B Bevers ,
Louis Fehrenbacher ,
Eduardo R Pajon ,
James L Wade ,
André Robidoux ,
Richard G Margolese ,
Joan James ,
Scott M Lippman ,
Carolyn D Runowicz ,
Patricia A Ganz ,
Steven E Reis ,
Worta McCaskill-Stevens ,
Leslie G Ford ,
V Craig Jordan ,
Norman Wolmark
Jun 21 2006
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.